J. Goldman & Co LP Makes New $504,000 Investment in PolyPid Ltd. $PYPD

J. Goldman & Co LP acquired a new stake in shares of PolyPid Ltd. (NASDAQ:PYPD) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 99,183 shares of the company’s stock, valued at approximately $504,000. J. Goldman & Co LP owned approximately 0.52% of PolyPid as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. ADAR1 Capital Management LLC bought a new position in shares of PolyPid in the 2nd quarter worth approximately $528,000. AIGH Capital Management LLC bought a new stake in shares of PolyPid during the second quarter valued at approximately $7,644,000. Renaissance Technologies LLC purchased a new stake in PolyPid in the first quarter worth $81,000. XTX Topco Ltd grew its stake in PolyPid by 50.0% in the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after purchasing an additional 10,888 shares during the period. Finally, Jane Street Group LLC bought a new position in PolyPid in the fourth quarter worth $66,000. Hedge funds and other institutional investors own 26.47% of the company’s stock.

Wall Street Analyst Weigh In

PYPD has been the subject of several recent research reports. Weiss Ratings raised PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 23rd. Craig Hallum set a $12.00 target price on shares of PolyPid in a research report on Wednesday, July 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $13.00 price target on shares of PolyPid in a research note on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $11.33.

PolyPid Stock Up 0.2%

Shares of PYPD opened at $5.11 on Thursday. PolyPid Ltd. has a twelve month low of $3.06 and a twelve month high of $5.73. The firm has a 50 day moving average of $4.80 and a 200 day moving average of $4.59. The company has a market capitalization of $97.50 million, a P/E ratio of -3.45 and a beta of 1.41.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.03. On average, sell-side analysts expect that PolyPid Ltd. will post -0.92 EPS for the current year.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.